Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Preceptorship on Non-Small-Cell and Small-Cell Lung Cancer 2024: Singapore
- Start date
- 09 Dec 2024
- End date
- 10 Dec 2024
- Location
- Singapore, Republic of Singapore
Learning objectives
- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of SCLC
Co-Chairs
- Tony S. K. Mok, Hong Kong, SAR China
- Solange Peters, Switzerland
Travel grant
In addition to the course registration and the hotel accommodation, a travel grant of maximum 600 euros is offered to selected applicants as a contribution versus their travel costs. The reimbursement will be processed after the course against original invoices/vouchers. Please be aware that visa costs are NOT covered by the travel grant and are the participant's responsibility.
Accreditation
The programme of this event will be accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Supported by
